Research programme: Kv1.3 potassium channel inhibitors - KPI Therapeutics

Drug Profile

Research programme: Kv1.3 potassium channel inhibitors - KPI Therapeutics

Alternative Names: KPI 190; KPI-150

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KPI Therapeutics
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Kv1.3 potassium channel inhibitors; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Eye disorders; Skin disorders

Most Recent Events

  • 27 Apr 2017 Preclinical trials in Atopic dermatitis in USA (Topical), before April 2017
  • 27 Apr 2017 Pharmacodynamics data from a preclinical trial in atopic dermatitis released by KPI Therapeutics
  • 10 Aug 2016 Preclinical trials in Eye disorders in USA (Topical) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top